

## **Congenital Hyperinsulinism International Designates Six Centers of Excellence (COE) for their Outstanding Multi-Disciplinary Congenital Hyperinsulinism Care**

**For Immediate Release: June 29, 2021**

Glen Ridge, NJ, June 29, 2021 - Congenital Hyperinsulinism International (CHI) is excited to announce that it has designated six Hyperinsulinism Centers of Excellence (COE). This honor recognizes centers that provide the highest level of multi-disciplinary care to congenital hyperinsulinism (HI) patients and their families, and an on-going commitment to research and collaboration.

“There are some superb institutions known for providing excellent HI care and participating in groundbreaking research, yet until now there has not been a review process or certificate awarded to these institutions for the care of those with HI.” - Julie Raskin, Executive Director, CHI



The awarded centers are:

- Congenital Hyperinsulinism Center at the Children's Hospital of Philadelphia, PA, United States
- Hyperinsulinism Center at Cook Children's Medical Center in Fort Worth, TX, United States
- Great Ormond Street Hospital Congenital Hyperinsulinism Service in London, in the United Kingdom
- Charite-Universitätsmedizin Berlin and the University Children's Hospital Duesseldorf partnership in Germany
- Collaborative Alliance on Congenital Hyperinsulinism headquartered in Magdeburg, Germany
- Northern Congenital Hyperinsulinism Service in Manchester and Liverpool, in the United Kingdom

CHI looks forward to continuing to work with these outstanding centers in support of the international hyperinsulinism community.

### **About COE**

The COE program launched in 2020 with the goal to designate specialist centers that demonstrate a consistent commitment to congenital hyperinsulinism patients, high quality care, research, and on-going collaboration with other medical professionals and patient advocates. The program was made possible through the Global Genes 2020 RARE Patient Impact Grant Program, the Chan Zuckerberg Initiative Rare As One Grant, and other generous donors. This is the first program that recognizes institutions for their work and care of those with HI. The designation application was developed by an international committee of HI specialists, clinicians, and patient/caregiver representatives who worked together to identify the requirements.

“Early identification and treatment of HI can lead to better patient outcomes. This program is meant to highlight the care needed to support patients and acknowledge the institutions that are leading the way in excellent care and research.” -Tai Pasquini, Research and Policy Director, CHI.

HI is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children. In most countries it occurs in approximately 1/25,000 to 1/50,000 births. Prolonged hypoglycemia can lead to brain damage or even death.

###

### **About CHI**

CHI, a 501(c)3, is a global organization dedicated to supporting children and adults born with HI. CHI is a leading source of funding for research for better treatments and cures, and the foremost advocate for increased awareness and better medical protocols for HI to reduce preventable brain damage and death from prolonged hypoglycemia.

### **Contact**

For more information about the COE program, please visit [www.congenitalhi.org/the-chi-centers-of-excellence-coe-program](http://www.congenitalhi.org/the-chi-centers-of-excellence-coe-program). You may also contact Tai Pasquini, CHI Research and Policy Director, at [tpasquini@congenitalhi.org](mailto:tpasquini@congenitalhi.org) or call 973-544-8372.